Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3882388 | 0.84 | SLC6A3 (0.42) | TSHRCYP2D6SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL10697123 | 0.83 | SLC6A3 (0.41) | TSHRCYP2D6SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL776890 | 0.80 | TSHR (0.48) | TSHRCYP2D6SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL11234861 | 0.79 | ALDH1A1 (0.47) | TSHRHTR2AHRH1RAB9AMAPK1 | |
| SCHEMBL576436 | 0.79 | IDO1 (0.50) | SLC6A4MTOR | |
| SCHEMBL3956655 | 0.78 | TSHR (0.46) | TSHRCYP2D6SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL576360 | 0.77 | TSHR (0.38) | TSHRCYP2D6SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL575898 | 0.75 | IDO1 (0.48) | TSHRCYP2D6SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL23713651 | 0.75 | TSHR (0.44) | TSHRCYP2D6SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL9188707 | 0.75 | TSHR (0.44) | TSHRCYP2D6SLC6A3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116759290-A | Passivation of germanium surfaces | 恩特格里斯公司 | 2023-09-15 | — | — | CN | claimed |
| CN-108028174-A | PASSIVATION OF GERMANIUM SURFACEs | 恩特格里斯公司 | 2018-05-11 | — | — | CN | claimed |
| CN-105390674-B | A kind of two ferrous selenides of sodium-ion battery/sulfur doping graphene anode material and preparation method thereof | 中南大学 | 2018-02-23 | — | — | CN | claimed |
| CN-107722049-A | A kind of preparation and its application of novel ionic double-core schiff bases titanium complex | 山西医科大学 | 2018-02-23 | — | — | CN | claimed |
| CN-105085341-B | N-substituted amide derivative and preparation method thereof | 西南石油大学 | 2017-03-22 | — | — | CN | claimed |
| CN-105390674-A | Iron diselenide/sulfur-doped graphene anode composite material for sodium-ion battery and preparation method of iron diselenide/sulfur-doped graphene anode composite material | UNIV CENTRAL SOUTH | 2016-03-09 | — | — | CN | claimed |
| CN-105085341-A | N-substituted amide derivative and preparation method thereof | UNIV SOUTHWEST PETROLEUM | 2015-11-25 | — | — | CN | claimed |
| CN-104496870-A | Catalytic synthesis method of sulfur-containing carboxylic acid compound and sulfur-containing amide compound | UNIV HUNAN | 2015-04-08 | — | — | CN | claimed |
| US-7960586-B2 | Purification of armodafinil | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-06-14 | — | — | US | claimed |
| EP-2159219-A2 | An improved process for the preparation of armodafinil | Teva Pharmaceutical Industries Ltd. (IL) | 2010-03-03 | — | — | EP | claimed |
| WO-2009025791-A2 | PURIFICATION OF ARMODAFINIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-02-26 | — | — | WO | claimed |
| US-20090048464-A1 | Purification of armodafinil | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-02-19 | — | — | US | claimed |
| CN-114075467-B | Polymeric surfactants for improving emulsion and flow characteristics at low temperatures | 雅富顿化学公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119032416-A | Protective sheet for semiconductor processing and method for manufacturing semiconductor device | 株式会社力森诺科 | 2024-11-26 | — | — | CN | disclosed |
| CN-118715223-A | Heterocyclic compounds as GCN2 and PERK kinase inhibitors | 德西费拉制药有限责任公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| WO-2007103221-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ARMODAFINIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103221-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ARMODAFINIL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-09-13 | — | — | WO | disclosed |
| EP-0281036-A2 | A process for preparing a polyarylene thioether | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1988-09-07 | — | — | EP | disclosed |
| EP-0227982-A1 | 1-H-Pyrido[3,2-b][1,4]thiazines | BAYER AG (DE) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048464-A1 | Purification of armodafinil | DHCR7, CYP4F8, CYP2C8 | TSHR 3973/4885CYP2D6 24/4885SLC6A3 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.